Gabor Rubovszky

7-9. Ráth György Str
Budapest, BU 1122, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Effective management of 5-fluorouracil-induced coronary vasospasm allowing chemotherapy continuation: a single-center observational study.

Effective management of 5-fluorouracil-induced coronary vasospasm allowing chemotherapy continuation: a single-center observational study.

Journal: Cardio-oncology (London, England)

Published: May 17, 2026

Cancer Diagnoses and Deaths in Hungary, 2011-2023: Nationwide Trends Before, During, and After the COVID-19 Pandemic.

Cancer Diagnoses and Deaths in Hungary, 2011-2023: Nationwide Trends Before, During, and After the COVID-19 Pandemic.

Journal: Cancers

Published: April 24, 2026

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 16, 2026

Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

Journal: Breast cancer research and treatment

Published: February 18, 2026

Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for the development of a national guideline.

Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for the development of a national guideline.

Journal: Magyar onkologia

Published: January 31, 2026

The Neutrophil-to-Lymphocyte Ratio May be the Best Serological Biomarker in Predicting Longer Survival in Neoadjuvant Treatment of Triple-Negative Breast Cancer.

The Neutrophil-to-Lymphocyte Ratio May be the Best Serological Biomarker in Predicting Longer Survival in Neoadjuvant Treatment of Triple-Negative Breast Cancer.

Journal: Cancer investigation

Published: December 05, 2025

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 27, 2025

Systemic treatment of breast cancer: professional guideline

Systemic treatment of breast cancer: professional guideline

Journal: Magyar onkologia

Published: June 16, 2025

Glucocorticoid Receptor Isoforms in Breast Cancer Raise Implications for Personalised Supportive Therapies.

Glucocorticoid Receptor Isoforms in Breast Cancer Raise Implications for Personalised Supportive Therapies.

Journal: International journal of molecular sciences

Published: September 13, 2024

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Journal: ESMO open

Published: September 04, 2024

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: July 17, 2024

Improvement in breast cancer survival across molecular subtypes in Hungary between 2011 and 2020: a nationwide, retrospective study.

Improvement in breast cancer survival across molecular subtypes in Hungary between 2011 and 2020: a nationwide, retrospective study.

Journal: Frontiers in oncology

Published: July 16, 2024

Showing 1-12 of 55

Last Updated: 09/26/2026